Johan Wallin is an accomplished professional in clinical pharmacology and pharmacometrics with extensive experience in the pharmaceutical industry. Currently serving as the Director of Clinical Pharmacology at BioInvent International AB since September 2021, Johan focuses on the implementation and execution of Model Based Drug Development and Clinical Pharmacology, collaborating closely with preclinical and translational groups. Prior to this role, Johan held a Director level position at Eli Lilly and Company, where responsibilities included developing clinical pharmacology submission packages for oncology agents and leading the pharmacometrics therapeutic area. Johan's career also includes positions at AstraZeneca, Uppsala University as a PhD student and lecturer, and Apoteket AB as a Clinical Pharmacist. Educational achievements encompass a PhD in Pharmacometrics from Uppsala University and a degree in Pharmacy from Uppsala University as well.